UBS Group’s Lixte Biotechnology Warrants LIXTW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-867
| Closed | -$125 | – | 10903 |
|
|
2025
Q3 | $125 | Buy |
+867
| New | +$172 | ﹤0.01% | 9885 |
|
|
2024
Q3 | – | Sell |
-4,088
| Closed | -$245 | – | 9827 |
|
|
2024
Q2 | $245 | Buy |
4,088
+235
| +6% | +$15 | ﹤0.01% | 9036 |
|
|
2024
Q1 | $193 | Buy |
3,853
+3,643
| +1,735% | +$242 | ﹤0.01% | 8739 |
|
|
2023
Q4 | $8 | Buy |
+210
| New | +$13 | ﹤0.01% | 9129 |
|
|
2023
Q2 | – | Sell |
-811
| Closed | -$70 | – | 9319 |
|
|
2023
Q1 | $70 | Buy |
+811
| New | +$92 | ﹤0.01% | 9292 |
|
|
2022
Q4 | – | Sell |
-7,623
| Closed | – | – | 10967 |
|
|
2022
Q3 | $0 | Buy |
7,623
+90
| +1% | +$11 | ﹤0.01% | 10669 |
|
|
2022
Q2 | $1K | Sell |
7,533
-1,067
| -12% | -$216 | ﹤0.01% | 9898 |
|
|
2022
Q1 | $2K | Buy |
8,600
+2,350
| +38% | +$602 | ﹤0.01% | 9644 |
|
|
2021
Q4 | $3K | Sell |
6,250
-2,274
| -27% | -$893 | ﹤0.01% | 9667 |
|
|
2021
Q3 | $5K | Sell |
8,524
-510
| -6% | -$335 | ﹤0.01% | 8542 |
|
|
2021
Q2 | $7K | Buy |
9,034
+1,855
| +26% | +$1.32K | ﹤0.01% | 8335 |
|
|
2021
Q1 | $6K | Sell |
7,179
-16,061
| -69% | -$15.3K | ﹤0.01% | 8241 |
|
|
2020
Q4 | $21K | Buy |
+23,240
| New | +$20.9K | ﹤0.01% | 6915 |
|
UBS Group's LIXTW Position: Q4 2025 in Review
UBS Group sold out of Lixte Biotechnology Warrants (LIXTW) in Q4 2025, closing a stake of 867 shares — an estimated $125 sold.
UBS Group first reported a position in LIXTW in Q4 2020 and held it in 13 quarters. The position peaked at $21K in Q4 2020. 0 funds tracked by Wall St. Rank hold LIXTW as of Q4 2025.
- UBS Group reported no remaining Lixte Biotechnology Warrants position as of Q4 2025 after selling out during the quarter.
- UBS Group sold 867 Lixte Biotechnology Warrants shares in Q4 2025, an estimated $125.
- UBS Group first reported a position in Lixte Biotechnology Warrants in Q4 2020 and held it in 13 quarters.
- UBS Group's Lixte Biotechnology Warrants position peaked at $21K in Q4 2020.
- 0 funds tracked by Wall St. Rank held Lixte Biotechnology Warrants as of Q4 2025.
Based on UBS Group's 13F filing for Q4 2025, filed 29 Jan 2026.